Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01987765|
Recruitment Status : Completed
First Posted : November 19, 2013
Results First Posted : April 29, 2014
Last Update Posted : April 29, 2014
|Condition or disease||Intervention/treatment|
|Conjunctivitis, Allergic||Drug: Relestat Ophthalmic Solution 0.05%|
|Study Type :||Observational|
|Actual Enrollment :||847 participants|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Relestat Ophthalmic Solution 0.05%
Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
Drug: Relestat Ophthalmic Solution 0.05%
Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
- Percentage of Patients Reporting Adverse Events [ Time Frame: Up to 10 Months ]An adverse event is any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
- Change From Baseline in Eye Symptoms Total Score on a 4-Point Scale [ Time Frame: Baseline, 2 Weeks ]Itchiness, conjunctival hyperaemia (redness), lacrimation (tearing), and foreign body sensation were each evaluated on a 4-point scale ranging from 0 (best) to 3 (worst). The eye symptom total score is the sum of the individual symptom scores and ranges from 0 (best) to 12 (worst). A negative number change from baseline indicates an improvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01987765
|Korea, Republic of|
|Gangwon-do, Korea, Republic of|
|Study Director:||Medical Director||Allergan|